Loading..

ImmunoGen, Inc. (IMGN) Report Analysis

Corporate Events

Positive

Immunogen, Inc. Announces Research Collaboratio...

2022-06-13 10:30:00

ImmunoGen Inc. announced a multi-year collaboration to research novel, first-in-class ADCs with Oxford BioTherapeutics, utilizing ImmunoGen's ...

Positive

ImmunoGen Presents Additional Efficacy and Safe...

2022-05-26 21:00:00

ImmunoGen, Inc. announced additional efficacy data from the pivotal SORAYA study evaluating mirvetuximab soravtansine (mirvetuximab) monothera...

Neutral

ImmunoGen, Inc. Presents at 2022 Jefferies Glob...

2022-05-25 20:30:00

ImmunoGen, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 09:30 AM. Venue: Marriott Marquis, New York City, New Yor...

Neutral

ImmunoGen, Inc. Presents at William Blair’s 42n...

2022-05-25 20:30:00

ImmunoGen, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-08-2022 12:20 PM. Venue: Loews Chicago Hotel, Chicag...

Positive

Immunogen Announces Acceptance of Biologics Lic...

2022-05-23 10:30:00

ImmunoGen, Inc. announced that the US Food and Drug Administration has accepted and filed the Biologics License Application for mirvetuximab s...

Neutral

ImmunoGen, Inc. Presents at H.C. Wainwright Glo...

2022-05-10 20:30:00

ImmunoGen, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Miami Beach Hotel, 4...

Neutral

Immunogen, Inc. Provides Revenue Guidance for 2022

2022-05-06 10:41:00

ImmunoGen, Inc. provided revenue guidance for 2022. For the period the Company expects revenues between $75 million and $85 million.

Neutral

ImmunoGen, Inc. - Shareholder/Analyst Call

2022-04-26 20:42:00

Annual Meeting of Shareholders

Neutral

ImmunoGen, Inc., Annual General Meeting, Jun 15, 2022

2022-04-26 20:42:00

ImmunoGen, Inc., Annual General Meeting, Jun 15, 2022, at 09:00 US Eastern Standard Time. Agenda: To fix the number of members of the Board of...

Neutral

ImmunoGen, Inc., Q1 2022 Earnings Call, May 06, 2022

2022-04-21 20:01:00

ImmunoGen, Inc., Q1 2022 Earnings Call, May 06, 2022

Neutral

ImmunoGen, Inc. Presents at CG 2022 Horizons in...

2022-03-31 20:30:00

ImmunoGen, Inc. Presents at CG 2022 Horizons in Oncology Virtual Conference, Apr-14-2022 08:00 AM. Speakers: Anna Berkenblit, Senior VP & Chie...

Neutral

ImmunoGen, Inc. Presents at 12th Annual World A...

2022-03-30 09:20:00

ImmunoGen, Inc. Presents at 12th Annual World ADC Conference 2022, Mar-29-2022 through Mar-31-2022. Venue: London, United Kingdom. Presentatio...

Neutral

ImmunoGen, Inc. Presents at Wells Fargo Annual ...

2022-03-29 20:00:00

ImmunoGen, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022 . Venue: Miami, Florida, United States. Speakers: Kristen Harrington...

Neutral

Hanson Wade Limited, 12th Annual World ADC Con...

2022-03-29 17:52:00

Hanson Wade Limited, 12th Annual World ADC Conference 2022, Mar 29, 2022 through Mar 31, 2022. Venue: London, United Kingdom.

Neutral

Wells Fargo Securities, LLC, Wells Fargo Annual...

2022-03-29 11:02:00

Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022. Venue: Miami, Florida, United States.

Positive

ImmunoGen, Inc. Submits Biologics License Appli...

2022-03-29 10:30:00

ImmunoGen, Inc. announced that it has submitted a Biologics License Application (BLA) under the accelerated approval pathway to the US Food an...

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Glo...

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami B...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Negative

ImmunoGen Appoints Mimi Huizinga as Senior Vice...

2022-01-31 11:30:00

ImmunoGen Inc. announced that Mimi Huizinga, MD, MPH, FACP has been appointed Senior Vice President and Head of Medical Affairs. Dr. Huizinga ...

Neutral

William Blair & Company, L.L.C., William Blair’...

2022-01-25 11:00:00

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022. Venue: Loews Chi...

Neutral

Canaccord Genuity Group Inc., CG 2022 Horizons ...

2022-01-24 17:55:00

Canaccord Genuity Group Inc., CG 2022 Horizons in Oncology Virtual Conference, Apr 14, 2022.

Positive

ImmunoGen Presents Initial Findings From the Ph...

2021-12-12 14:30:00

ImmunoGen, Inc. announced that updated initial safety and efficacy findings from the Phase 1b/2 study of IMGN632 in combination with Vidaza® (...

Negative

ImmunoGen, Inc. has completed a Follow-on Equit...

2021-12-02 00:00:00

ImmunoGen, Inc. has completed a Follow-on Equity Offering in the amount of $257.126364 million. Security Name: Common Stock Security Type:...

Neutral

ImmunoGen, Inc. - Special Call

2021-11-30 11:30:00

To discuss positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy of mirvetuximab soravtansine (mirvetuximab)...

Negative

ImmunoGen, Inc. has filed a Follow-on Equity Of...

2021-11-30 00:00:00

ImmunoGen, Inc. has filed a Follow-on Equity Offering in the amount of $175 million. Security Name: Common Stock Security Type: Common Stock

Neutral

ImmunoGen, Inc. Presents at Piper Sandler 33rd ...

2021-11-22 15:06:00

ImmunoGen, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Negative

ImmunoGen Inc Appoints Tracey L. Mccain to Its ...

2021-11-17 21:01:00

ImmunoGen Inc. announced the appointment of Tracey L. McCain, Esq. to its Board of Directors. Ms. McCain has more than 20 years of legal, mana...

Negative

ImmunoGen, Inc. Appoints Kristen Harrington-Smi...

2021-11-16 11:30:00

ImmunoGen Inc. announced that Kristen Harrington-Smith has been appointed Senior Vice President and Chief Commercial Officer. Ms. Harrington-S...

Positive

ImmunoGen Inc. Announces Initial Safety and Eff...

2021-11-04 13:00:00

ImmunoGen Inc. announced initial safety and efficacy findings from its Phase 1b/2 study of IMGN632 in combination with Vidaza (azacitidine) an...

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Neutral

ImmunoGen, Inc. Provides Updated Financial Guid...

2021-10-29 10:44:00

ImmunoGen, Inc. provided updated financial guidance for 2021. For 2021, the company now expects revenues between $65 million and $75 million.

Neutral

ImmunoGen, Inc., Q3 2021 Earnings Call, Oct 29, 2021

2021-10-14 20:01:00

ImmunoGen, Inc., Q3 2021 Earnings Call, Oct 29, 2021

Neutral

ImmunoGen, Inc. Presents at Longwood Healthcare...

2021-09-28 18:44:00

ImmunoGen, Inc. Presents at Longwood Healthcare Leaders Conference, Oct-04-2021 02:20 PM. Speakers: Stacy A. Coen, Senior VP & Chief Business Officer.

Neutral

Longwood Fund, Longwood Healthcare Leaders Conf...

2021-09-28 13:09:00

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021.

Negative

ImmunoGen Inc. Appoints Helen M. Thackray, MD t...

2021-09-22 20:01:00

ImmunoGen Inc. announced the appointment of Helen M. Thackray, MD, FAAP to its Board of Directors. Dr. Thackray has over 25 years of biopharma...

Neutral

ImmunoGen, Inc. has filed a Shelf Registration ...

2021-08-09 00:00:00

ImmunoGen, Inc. has filed a Shelf Registration in the amount of $11.42 million. Security Name: Common Stock Securities Offered: 2,000,000 ...

Neutral

ImmunoGen, Inc. has filed a Shelf Registration ...

2021-08-09 00:00:00

ImmunoGen, Inc. has filed a Shelf Registration in the amount of $37.686 million. Security Name: Common Stock Securities Offered: 6,600,000...

Neutral

American Society Of Hematology, 63rd American S...

2021-07-31 11:04:00

American Society Of Hematology, 63rd American Society of Hematologists Annual Meeting & Exposition, Dec 11, 2021 through Dec 15, 2021. Venue: ...

Neutral

ImmunoGen, Inc. Presents at 63rd American Socie...

2021-07-31 06:09:00

ImmunoGen, Inc. Presents at 63rd American Society of Hematologists Annual Meeting & Exposition, Dec-11-2021 . Venue: Georgia World Congress Ce...

Neutral

Immunogen, Inc. Maintains Revenue Guidance for ...

2021-07-30 10:30:00

ImmunoGen, Inc. maintained revenue guidance for the year 2021. For the year, the company revenues between $65 million and $75 million.

Neutral

ImmunoGen, Inc., Q2 2021 Earnings Call, Jul 30, 2021

2021-07-15 20:01:00

ImmunoGen, Inc., Q2 2021 Earnings Call, Jul 30, 2021

Positive

Immunogen, Inc. Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates

2022-06-13 10:30:00

ImmunoGen Inc. announced a multi-year collaboration to research novel, first-in-class ADCs with Oxford BioTherapeutics, utilizing ImmunoGen's proprietary linker-payload technology directed to novel targets identified via OBT's proprietary OGAP discovery platform. The companies will support these research and development efforts through joint funding and by using their respective proprietary technologies. As part of the agreement, OBT will receive an upfront payment from ImmunoGen, reflecting OBT's preclinical programs to be included in the collaboration. After antibodies generated by OBT have been coupled with ImmunoGen's proprietary linker-payload technology, each company will have the opportunity to select one or more development programs to further develop on its own. Each company will be eligible to receive milestone payments based on the achievement of pre-specified development and regulatory milestones, as well as tiered royalties as a percentage of worldwide commercial sales, with respect to each program selected by the other company. Once a company has chosen a given program, it will be solely responsible for all R&D costs associated with that specific program. ImmunoGen's portfolio is comprised of next-generation maytansinoid, DNA-acting, and novel camptothecin toxins and proprietary linkers. This collaboration will utilize novel targets identified by OBT combined with ImmunoGen's proprietary toxins and associated linkers. OBT has clinical experience with ImmunoGen's ADC platform and DM4 payload, which is utilized in OBT's lead program OBT076, an ADC currently in clinical trials as a monotherapy, as well as in combination with checkpoint inhibitors, in patients with advanced or refractory solid tumors, including gastric, bladder, ovarian, and lung cancer.

Positive

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

2022-05-26 21:00:00

ImmunoGen, Inc. announced additional efficacy data from the pivotal SORAYA study evaluating mirvetuximab soravtansine (mirvetuximab) monotherapy in patients with folate receptor alpha (FRa)-high platinum-resistant ovarian cancer who have been previously treated with Avastin® (bevacizumab) and an integrated safety summary of single-agent mirvetuximab across multiple studies in patients with FRa-positive recurrent ovarian cancer. These findings will be highlighted in two posters at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 3-7, 2022. The data from SORAYA have been selected for the Best of ASCO® Program.

Neutral

ImmunoGen, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 09:30 AM

2022-05-25 20:30:00

ImmunoGen, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 09:30 AM. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

ImmunoGen, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-08-2022 12:20 PM

2022-05-25 20:30:00

ImmunoGen, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-08-2022 12:20 PM. Venue: Loews Chicago Hotel, Chicago, Illinois, United States.

Positive

Immunogen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review

2022-05-23 10:30:00

ImmunoGen, Inc. announced that the US Food and Drug Administration has accepted and filed the Biologics License Application for mirvetuximab soravtansine monotherapy in patients with folate receptor alpha (FRa)-high platinum-resistant ovarian cancer who have been previously treated with 1 to 3 prior systemic treatments. The application has been granted Priority Review designation and FDA has set a Prescription Drug User Fee Act action date of November 28, 2022. Priority Review designation is granted to applications for therapies that may offer significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications and shortens the FDA review period to six months following acceptance. The BLA seeks approval of mirvetuximab soravtansine under the FDA’s accelerated approval pathway, which was instituted to allow for expedited development of drugs that treat serious conditions and provide a meaningful advantage over available therapies based on a surrogate endpoint and is based on results from the pivotal Phase 3 SORAYA trial. Top-line data from SORAYA were announced in November 2021 and full data from the study were presented at the Society of Gynecologic Oncology 2022 Annual Meeting. ImmunoGen continues to enroll patients in the confirmatory MIRASOL trial, which is intended to convert the potential accelerated approval to full approval, and expects to announce top-line data from this study in early 2023.

Neutral

ImmunoGen, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM

2022-05-10 20:30:00

ImmunoGen, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States. Speakers: Susan Altschuller, Senior VP & CFO.

Neutral

Immunogen, Inc. Provides Revenue Guidance for 2022

2022-05-06 10:41:00

ImmunoGen, Inc. provided revenue guidance for 2022. For the period the Company expects revenues between $75 million and $85 million.

Neutral

ImmunoGen, Inc. - Shareholder/Analyst Call

2022-04-26 20:42:00

Annual Meeting of Shareholders

Neutral

ImmunoGen, Inc., Annual General Meeting, Jun 15, 2022

2022-04-26 20:42:00

ImmunoGen, Inc., Annual General Meeting, Jun 15, 2022, at 09:00 US Eastern Standard Time. Agenda: To fix the number of members of the Board of Directors at nine; to elect nine members of the Board of Directors to hold office until the next annual meeting of shareholders and until their successors are duly elected and qualified; to approve an amendment to company's Restated Articles of Organization to increase the number of authorized shares from 300,000,000 to 600,000,000; to approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in this proxy statement; and to ratify the appointment of Ernst & Young LLP as company's independent registered public accounting firm for the year ending December 31, 2022.

Neutral

ImmunoGen, Inc., Q1 2022 Earnings Call, May 06, 2022

2022-04-21 20:01:00

ImmunoGen, Inc., Q1 2022 Earnings Call, May 06, 2022

Neutral

ImmunoGen, Inc. Presents at CG 2022 Horizons in Oncology Virtual Conference, Apr-14-2022 08:00 AM

2022-03-31 20:30:00

ImmunoGen, Inc. Presents at CG 2022 Horizons in Oncology Virtual Conference, Apr-14-2022 08:00 AM. Speakers: Anna Berkenblit, Senior VP & Chief Medical Officer.

Neutral

ImmunoGen, Inc. Presents at 12th Annual World ADC Conference 2022, Mar-29-2022 through Mar-31-2022

2022-03-30 09:20:00

ImmunoGen, Inc. Presents at 12th Annual World ADC Conference 2022, Mar-29-2022 through Mar-31-2022. Venue: London, United Kingdom. Presentation Date & Speakers: Mar-30-2022, Mimi Huizinga, SVP, Head of Medical Affairs.

Neutral

ImmunoGen, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022

2022-03-29 20:00:00

ImmunoGen, Inc. Presents at Wells Fargo Annual Biotech Forum, Apr-12-2022 . Venue: Miami, Florida, United States. Speakers: Kristen Harrington-Smith, Senior VP & Chief Commercial Officer, Susan Altschuller, Senior VP & CFO.

Neutral

Hanson Wade Limited, 12th Annual World ADC Conference 2022, Mar 29, 2022 through Mar 31, 2022

2022-03-29 17:52:00

Hanson Wade Limited, 12th Annual World ADC Conference 2022, Mar 29, 2022 through Mar 31, 2022. Venue: London, United Kingdom.

Neutral

Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022

2022-03-29 11:02:00

Wells Fargo Securities, LLC, Wells Fargo Annual Biotech Forum, Apr 12, 2022 through Apr 13, 2022. Venue: Miami, Florida, United States.

Positive

ImmunoGen, Inc. Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

2022-03-29 10:30:00

ImmunoGen, Inc. announced that it has submitted a Biologics License Application (BLA) under the accelerated approval pathway to the US Food and Drug Administration (FDA) for mirvetuximab soravtansine monotherapy in patients with folate receptor alpha (FRa)-high platinum-resistant ovarian cancer who have been previously treated with 1 to 3 prior systemic treatments. The submission is based on results from the pivotal Phase 3 SORAYA trial. Top-line data from SORAYA were announced in November 2021 and full data from the study were presented this month at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting. The FDA has a 60-day review period to determine whether the BLA is complete and acceptable for filing. ImmunoGen has requested priority review of the application and, if granted, the review will be completed within six months of the filing date. The BLA was submitted under the FDA’s accelerated approval pathway, instituted to allow for expedited development of drugs that treat serious conditions and provide a meaningful advantage over available therapies based on a surrogate endpoint. ImmunoGen continues to enroll patients in the confirmatory MIRASOL trial designed to generate the randomized data needed for full approval and expects to announce top-line data from this study in the third quarter of 2022. The FDA granted Orphan Drug Designation to mirvetuximab soravtansine for the treatment of ovarian cancer in April 2015. In June 2018, the FDA granted mirvetuximab soravtansine Fast Track Designation for the treatment of patients with medium to high FRa-positive platinum-resistant ovarian cancer who received at least one, but no more than three, prior systemic treatment regimens, and for whom single-agent chemotherapy is appropriate as the next line of therapy. This designation is intended to facilitate the development and expedite the review of drugs that treat serious and life-threatening conditions. Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent, to kill the targeted cancer cells. ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Negative

ImmunoGen Appoints Mimi Huizinga as Senior Vice President and Head of Medical Affairs

2022-01-31 11:30:00

ImmunoGen Inc. announced that Mimi Huizinga, MD, MPH, FACP has been appointed Senior Vice President and Head of Medical Affairs. Dr. Huizinga joins ImmunoGen from Rafael Holdings where she served as Chief Medical Officer and Head of Research and Development and was responsible for leading the Company’s discovery and development programs. Prior to joining Rafael, she served as SVP, Head of US Oncology Medical for Novartis, overseeing the clinical development and medical affairs activities of the Novartis oncology portfolio in the US. Before leading the medical function, Dr. Huizinga built and led the strategic data and digital function for the US Oncology business unit at Novartis. During her time at Novartis, she participated in more than a dozen product and indication launches.

Neutral

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022

2022-01-25 11:00:00

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022. Venue: Loews Chicago Hotel, Chicago, Illinois, United States.

Neutral

Canaccord Genuity Group Inc., CG 2022 Horizons in Oncology Virtual Conference, Apr 14, 2022

2022-01-24 17:55:00

Canaccord Genuity Group Inc., CG 2022 Horizons in Oncology Virtual Conference, Apr 14, 2022.

Positive

ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH

2021-12-12 14:30:00

ImmunoGen, Inc. announced that updated initial safety and efficacy findings from the Phase 1b/2 study of IMGN632 in combination with Vidaza® (azacitidine) and Venclexta® (venetoclax) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) were presented in an oral session at the 63rdAmerican Society of Hematology (ASH) Annual Meeting. Data for IMGN632 in frontline patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) were also presented in a poster session at the conference.

Negative

ImmunoGen, Inc. has completed a Follow-on Equity Offering in the amount of $257.126364 million.

2021-12-02 00:00:00

ImmunoGen, Inc. has completed a Follow-on Equity Offering in the amount of $257.126364 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 11,636,364 Price\Range: $6.6 Discount Per Security: $0.396 Security Name: Pre-funded warrants Security Type: Equity Warrant Securities Offered: 27,363,636 Price\Range: $6.59 Discount Per Security: $0.396

Neutral

ImmunoGen, Inc. - Special Call

2021-11-30 11:30:00

To discuss positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy of mirvetuximab soravtansine (mirvetuximab) monotherapy in patients with folate receptor alpha (FRa)-high platinum-resistant ovarian cancer who have been previously treated with Avastin (bevacizumab)

Negative

ImmunoGen, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

2021-11-30 00:00:00

ImmunoGen, Inc. has filed a Follow-on Equity Offering in the amount of $175 million. Security Name: Common Stock Security Type: Common Stock

Neutral

ImmunoGen, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021

2021-11-22 15:06:00

ImmunoGen, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Negative

ImmunoGen Inc Appoints Tracey L. Mccain to Its Board of Directors

2021-11-17 21:01:00

ImmunoGen Inc. announced the appointment of Tracey L. McCain, Esq. to its Board of Directors. Ms. McCain has more than 20 years of legal, management, and transactional experience in the biopharmaceutical industry and currently serves as the Executive Vice President and Chief Legal and Compliance Officer at Blueprint Medicines Corporation. Prior to joining Blueprint, she served as Senior Vice President and Head of Legal for Sanofi Genzyme, was a member of the executive leadership team, and a member of the leadership team for Sanofi’s global legal department.

Negative

ImmunoGen, Inc. Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer

2021-11-16 11:30:00

ImmunoGen Inc. announced that Kristen Harrington-Smith has been appointed Senior Vice President and Chief Commercial Officer. Ms. Harrington-Smith joins ImmunoGen from Novartis Pharmaceuticals, where she served as US Commercial Head of Hematology and led the teams responsible for a broad portfolio of therapies in both benign and malignant hematologic diseases. Prior to this, Ms. Harrington-Smith held roles of increasing responsibility at Novartis, including leading the commercial launch of Kymriah®, the first CAR-T cell therapy, building management, sales, and marketing teams, and supporting the launch of Gilenya® for the treatment of multiple sclerosis. Ms. Harrington-Smith received a BA from Williams College and an MBA from the Kenan-Flagler Business School at the University of North Carolina.

Positive

ImmunoGen Inc. Announces Initial Safety and Efficacy Findings from Its Phase 1b/2 Study of IMGN632

2021-11-04 13:00:00

ImmunoGen Inc. announced initial safety and efficacy findings from its Phase 1b/2 study of IMGN632 in combination with Vidaza (azacitidine) and Venclexta (venetoclax) (triplet) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). These data will be presented in an oral session at the 63rdAmerican Society of Hematology (ASH) Annual Meeting December 11-14. Data for IMGN632 in frontline patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) will also be presented in a poster session at ASH. IMGN632 is a CD123-targeting ADC comprised of a high-affinity antibody coupled to a DNA-alkylating payload of the novel IGN (indolinobenzodiazepine pseudodimer) class. IGNs are designed to have high potency against leukemic blasts while demonstrating less toxicity to normal marrow progenitors than other DNA-targeting payloads. Key findings include: IMGN632 was administered to 35 patients at dose levels ranging from 15 to 45 mcg/kg, azacitidine at 50-75 mg/m2 for 7 days, and venetoclax at 400 mg daily for 8-21 days; IMGN632 continued to display a manageable safety profile in R/R AML patients; The most common treatment emergent adverse events (TEAE) all grades [grade 3+ events] seen in >20% of patients were infusion-related reactions (IRR, 37% [3%]), febrile neutropenia (26% [23%]), hypophosphatemia (26% [3%]), dyspnea (26% [6%]), pneumonia (20% [14%]), and fatigue (20% [0%]); No tumor lysis syndrome, veno-occlusive disease, capillary leak, or cytokine release were reported. Efficacy: Responses were seen across all cohorts/doses and schedules (efficacy evaluable population, n=29). The objective response rate (ORR) was 55%, with a composite complete remission (CCR) rate of 31% (1 CR, 4 CRh, 2 CRp, 2 CRi); Higher intensity cohorts (n=20) were associated with higher response rates including an ORR of 75% and a CCR rate of 40%; Significant activity was also observed in the FLT3 mutant subset (n=7), with ORR and CCR rates of 100% and 71%, respectively. In addition, data from three frontline BPDCN patients who received IMGN632 prior to commencement of the enrolling pivotal cohort will be highlighted in a poster presentation at ASH. All three patients achieved a clinical complete remission (CRc).

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Neutral

ImmunoGen, Inc. Provides Updated Financial Guidance for 2021

2021-10-29 10:44:00

ImmunoGen, Inc. provided updated financial guidance for 2021. For 2021, the company now expects revenues between $65 million and $75 million.

Neutral

ImmunoGen, Inc., Q3 2021 Earnings Call, Oct 29, 2021

2021-10-14 20:01:00

ImmunoGen, Inc., Q3 2021 Earnings Call, Oct 29, 2021

Neutral

ImmunoGen, Inc. Presents at Longwood Healthcare Leaders Conference, Oct-04-2021 02:20 PM

2021-09-28 18:44:00

ImmunoGen, Inc. Presents at Longwood Healthcare Leaders Conference, Oct-04-2021 02:20 PM. Speakers: Stacy A. Coen, Senior VP & Chief Business Officer.

Neutral

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021

2021-09-28 13:09:00

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021.

Negative

ImmunoGen Inc. Appoints Helen M. Thackray, MD to its Board of Directors

2021-09-22 20:01:00

ImmunoGen Inc. announced the appointment of Helen M. Thackray, MD, FAAP to its Board of Directors. Dr. Thackray has over 25 years of biopharmaceutical, clinical research, and bench research experience. Currently, Dr. Thackray is the Chief Research and Development Officer for BioCryst Pharmaceuticals, Inc., where she oversees research and development activities from discovery through registration and defines the strategic direction of the Company's pipeline.

Neutral

ImmunoGen, Inc. has filed a Shelf Registration in the amount of $11.42 million.

2021-08-09 00:00:00

ImmunoGen, Inc. has filed a Shelf Registration in the amount of $11.42 million. Security Name: Common Stock Securities Offered: 2,000,000 Transaction Features: ESOP Related Offering

Neutral

ImmunoGen, Inc. has filed a Shelf Registration in the amount of $37.686 million.

2021-08-09 00:00:00

ImmunoGen, Inc. has filed a Shelf Registration in the amount of $37.686 million. Security Name: Common Stock Securities Offered: 6,600,000 Transaction Features: ESOP Related Offering

Neutral

American Society Of Hematology, 63rd American Society of Hematologists Annual Meeting & Exposition, Dec 11, 2021 through Dec 15, 2021

2021-07-31 11:04:00

American Society Of Hematology, 63rd American Society of Hematologists Annual Meeting & Exposition, Dec 11, 2021 through Dec 15, 2021. Venue: Georgia World Congress Center, Atlanta, Georgia, United States.

Neutral

ImmunoGen, Inc. Presents at 63rd American Society of Hematologists Annual Meeting & Exposition, Dec-11-2021

2021-07-31 06:09:00

ImmunoGen, Inc. Presents at 63rd American Society of Hematologists Annual Meeting & Exposition, Dec-11-2021 . Venue: Georgia World Congress Center, Atlanta, Georgia, United States.

Neutral

Immunogen, Inc. Maintains Revenue Guidance for the Year 2021

2021-07-30 10:30:00

ImmunoGen, Inc. maintained revenue guidance for the year 2021. For the year, the company revenues between $65 million and $75 million.

Neutral

ImmunoGen, Inc., Q2 2021 Earnings Call, Jul 30, 2021

2021-07-15 20:01:00

ImmunoGen, Inc., Q2 2021 Earnings Call, Jul 30, 2021

Fundamental Summary

ImmunoGen's financial results from Q1 demonstrated decent performance, but will likely only help ImmunoGen remain on par with its peers. This typically translates into the stock performing on par with market performance for the upcoming quarter. As such, ImmunoGen received an overall score of 64 and a HOLD recommendation.

ImmunoGen reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 38.08 million compared to USD 15.71 million a year ago. Net loss was USD 24.15 million compared to USD 34.05 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.17 a year ago. Diluted loss per share from continuing operations was USD 0.1 compared to USD 0.17 a year ago.

Business Description

ImmunoGen, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen was founded in 1980 and is headquartered in Waltham, Massachusetts.

Sector Overview

ImmunoGen is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. ImmunoGen's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 481.7 -8.4% 67
Liabilities 175.2 -12.5% 52
Price to Book 2.8 -45.0% 48
Cash & Equivalents 437.7 -8.6% 61
Equity 306.5 -5.9% 64
EBITDA -117.1 3.9% 73
Total Revenues 92.2 32.0% 40
Parameter Value Change Score
Return on Equity -64.6 3.7% 71
Net Cashflow 154.5 -16.4% 77
Capital Expenditure -0.8 40.9% 95
Asset Turnover 0.2 40.5% 95
Free Cashflow -0.8 8.3% 79

* All values are TTM

The below chart reflects ImmunoGen's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While ImmunoGen's peer average final assessment score stands on 62.0, ImmunoGen's score is 64.

  •  IMGN
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 22 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 23 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 24 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 26 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 28 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 30 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 31 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 32 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 33 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 35 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. ImmunoGen's stock is now priced above its 50-day, but below its 5-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), ImmunoGen's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 57.

Bearish 57
Close Price 4.29
52W Low 3.15
52W High 7.5
5D MA 4.31
50D MA 4.12
200D MA 5.41
MACD 0.07
RSI 5.48
STOCH 91.94

Balance Sheet Analysis

ImmunoGen's recently published balance sheet showed overall, underwhelming numbers. Both Book Value Factors and Liabilities were particularly concerning. ImmunoGen publishes concerning book value factor metrics in this report. price to book ratio (P/B) now sits at 2.8 and represents -45.0% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. Their book value factor metrics are even more concerning when compared to their peers. Consequently, their book value factors movement received a grade of 48. Also, In terms of liabilities, ImmunoGen published uninspiring results. Their reported liabilities were 175.2, representing a -12.5% change from the previous report. ImmunoGen's liabilities changes appear mediocre compared to their peers. Contextually, they convey that management finds balancing asset growth, resource allocation, and liabilities challenging. Its liabilities movement component, therefore, received a grade of 52. However, one encouraging metric, Assets, stood out. The company's assets section could set high expectations for ImmunoGen's future attractiveness, as they went to 481.7, which is a -8.4% change from the last period. This performance is interesting in comparison to its peers and competitors. The company's asset component, therefore, received a grade of 67. Consequently, its balance sheet earned a rank of 56.

Parameter Value Change Score
Assets 481.7 -8.4% 67
Liabilities 175.2 -12.5% 52
Price to Book 2.8 -45.0% 48
Cash & Equivalents 437.7 -8.6% 61
Equity 306.5 -5.9% 64
* All values are TTM

The below chart describes ImmunoGen's performance as reflected on its balance sheet with respect to its peers. While ImmunoGen received a balance sheet score of 56, the average of its peers stands on 62.0.

  •  IMGN
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Natera, Inc. 3.6B 73 65 43 95 42 54 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 22 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 23 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 24 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 26 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 28 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 30 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 31 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 32 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 33 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 35 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

EBITDA and Return Factors stand out as the most significant drivers of ImmunoGen's income statement's strength. ImmunoGen reported impressive EBITDA this period. At filing, EBITDA was reported as -117.1, representing 3.9% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Its EBITDA metrics highlight an impressive overall financial performance, which is expected to continue moving forward. The company's EBITDA movement, therefore, received a grade of 73. Also, In this filing, ImmunoGen reported a return on equity (ROE) ratio of -64.6, which represents a change of 3.7%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Consequently, their return factors received a grade of 71. At the same time, one critical income statement metric, Revenue Efficiency, was notably weak. ImmunoGen reported discouraging numbers for its revenue efficiency. As of the current filing, they were reported as 92.2 and represented 32.0% change from the previous period. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency, specifically in contrast to their industry peers', isn't encouraging. As a result, their revenue efficiency earned a score of 40. Therefore, it received a score of 64.

Parameter Value Change Score
EBITDA -117.1 3.9% 73
Total Revenues 92.2 32.0% 40
Return on Equity -64.6 3.7% 71
* All values are TTM

The below chart describes ImmunoGen's performance as reflected on its income statement with respect to its peers. While ImmunoGen received a income statement score of 64 , the average of its peers stands on 65.0.

  •  IMGN
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Natera, Inc. 3.6B 52 51 78 52 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 22 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 23 1
Insmed Incorporated 2.4B 51 58 73 57 24 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 26 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 28 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 29 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 30 1
IVERIC bio, Inc. 1.1B 84 58 79 70 31 1
FibroGen, Inc. 1.0B 48 74 63 67 32 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 33 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 35 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Overall, ImmunoGen's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. ImmunoGen's management was effective in improving its CapEx, which now sits at -0.8 and represents 40.9% change from the previous report. This remarkable CapEx growth is expected to reinforce upward momentum for its's stock price going forward. Consequently, their CapEx movement received a grade of 95. Also, ImmunoGen is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.2, representing a 40.5% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. Its asset turnover metrics are especially remarkable relative to their peers. We believe the stock price has room to grow to reflect its intrinsic value accurately. Therefore, its asset turnover movement earned a score of 95. On the other hand, Net Cash Flow, jumped out as looking problematic. ImmunoGen's net cash flow metrics were 154.5 according to their current filing, which represents a -16.4% change from the previous report. Their net cash flow momentum should be a cause for concern and could bring negative momentum for ImmunoGen's stock price going forward. Its net cash flow, therefore, received a grade of 77. Because its management is doing an excellent job managing these critical metrics, the cash flow was given a score of 87.

Parameter Value Change Score
Net Cashflow 154.5 -16.4% 77
Capital Expenditure -0.8 40.9% 95
Asset Turnover 0.2 40.5% 95
Free Cashflow -0.8 8.3% 79
* All values are TTM

The below chart describes ImmunoGen's performance as reflected on its cash flow with respect to its peers. While ImmunoGen received a cash flow score of 87, the average of its peers stands on 68.0.

  •  IMGN
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Natera, Inc. 3.6B 52 54 56 84 58 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 22 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 23 1
Insmed Incorporated 2.4B 79 80 61 89 82 24 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 26 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 28 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 29 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 30 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 31 1
FibroGen, Inc. 1.0B 86 74 48 87 84 32 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 33 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 35 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.